Growth Metrics

Barinthus Biotherapeutics (BRNS) Debt to Equity (2021)

Barinthus Biotherapeutics (BRNS) has disclosed Debt to Equity for 1 consecutive years, with $0.0 as the latest value for Q4 2021.

  • For Q4 2021, Debt to Equity changed N/A year-over-year to $0.0; the TTM value through Dec 2021 reached $0.0, changed N/A, while the annual FY2021 figure was $0.0, N/A changed from the prior year.
  • Debt to Equity hit $0.0 in Q4 2021 for Barinthus Biotherapeutics.
  • Across five years, Debt to Equity topped out at $0.0 in Q4 2021 and bottomed at $0.0 in Q4 2021.